Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

An 8-week Open-label, Multicenter Randomized Study of Accelerated and Slower Switching to Xanomeline/Trospium Following Atypical Antipsychotic Treatment to Assess the Safety, Tolerability, and Efficacy in Participants With DSM-5 Schizophrenia

NCT06924255 is registered in ClinicalTrials.gov with Collaborative Neuroscience Research, LLC as lead sponsor.

NCT NCT06924255
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06924255 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
An 8-week Open-label, Multicenter Randomized Study of Accelerated and Slower Switching to Xanomeline/Trospium Following Atypical Antipsychotic Treatment to Assess the Safety, Tolerability, and Efficacy in Participants With DSM-5 Schizophrenia
Lead sponsor
Collaborative Neuroscience Research, LLC
Phase
Phase 4
Overall status
Not yet recruiting
Start date
April 30, 2025
Completion date
December 31, 2025
Enrollment
100 (estimated)
Sites
7

Conditions

As the registry lists them; a condition with its own page is linked.

schizophrenia disorders